^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H3-targeted antibody-drug conjugate

    Related drugs:
    2d
    QLC5508 in Participants With Metastatic Prostate Cancer (clinicaltrials.gov)
    P3, N=700, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    docetaxel • MHB088C
    2d
    BGB-C354-101: A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Completed, BeOne Medicines | Active, not recruiting --> Completed | N=120 --> 63 | Trial completion date: Jan 2027 --> May 2026 | Trial primary completion date: Dec 2026 --> May 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Tevimbra (tislelizumab-jsgr)
    5d
    A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) (clinicaltrials.gov)
    P1/2, N=134, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    ifinatamab deruxtecan (DS-7300)
    8d
    A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (clinicaltrials.gov)
    P3, N=494, Not yet recruiting, Hansoh BioMedical R&D Company
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan • risvutatug rezetecan (GSK5764227)
    9d
    QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1 trial
    |
    Nubeqa (darolutamide) • itraconazole • MHB088C • rifampicin
    9d
    A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=212, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    enzalutamide • abiraterone acetate • MHB088C
    11d
    Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3- and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer. (PubMed, Mol Cancer Ther)
    The compelling preclinical efficacy across cancer models with varying levels of target antigen expression and its exceptional plasma stability support the translational relevance of GenSci143. These results indicate that GenSci143 is a promising therapeutic candidate for castration resistant PCa and potentially other malignancies, warranting its further clinical development.
    Preclinical • Journal
    |
    CD276 (CD276 Molecule)
    13d
    A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors (clinicaltrials.gov)
    P1, N=155, Recruiting, NEOK Bio, Inc.
    New P1 trial • First-in-human
    14d
    300640: A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) (2025-523997-18-00)
    P1/2, N=14, Not yet recruiting, Glaxosmithkline Research & Development Limited
    New P1/2 trial
    |
    risvutatug rezetecan (GSK5764227)
    14d
    A clinical trial of ifinatamab deruxtecan in people under age 18 who have certain types of cancer (MK-9999-01D) (2025-522339-32-00)
    P1/2, N=4, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    ifinatamab deruxtecan (DS-7300)
    15d
    A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=438, Active, not recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD276 (CD276 Molecule)
    |
    topotecan • RG6919
    19d
    A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) (clinicaltrials.gov)
    P1/2, N=184, Not yet recruiting, GlaxoSmithKline
    New P1/2 trial • Pan tumor
    |
    CD276 (CD276 Molecule)
    |
    Idafang (ivonescimab) • risvutatug rezetecan (GSK5764227)